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Abstract
Purpose To examine quality of life (QoL), health status,
sexual function, and anxiety in patients with primary
hematuria who later appear to have bladder cancer (BC)
and patients with other diagnoses.
Methods From July 2007 to July 2010, 598 patients with
primary hematuria were enrolled in this prospective, mul-
ticenter study. Questionnaires (WHOQOL-BREF, SF-12,
IIEF, STAI-10-item Trait) were completed before cystos-
copy. Diagnosis was subsequently derived from medical
files. BC patients were compared with patients with other
causes of hematuria.
Results Cancer was diagnosed in 131 patients (21.9 %),
including 102 patients (17.1 %) with BC. No differences
were found in the WHOQOL-BREF versus SF-12 psy-
chological or physical health domains. The erectile func-
tion was significantly worse in the BC group (9.3 vs. 14.6
for OC, p = 0.02). Patients with muscle-invasive BC
(MIBC) had the lowest percentage anxious personalities of
all BC patients (p = 0.04).
Conclusions Cancer was found in 21.9 % of the patients
with hematuria. Pre-diagnosis patients with BC have
comparable QoL and HS to patients with OC. Erectile
dysfunction was highest in patients with BC. MIBC
patients had the lowest percentage anxious personalities of
the patients with BC.
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Trait scale short form
X-IVP Rontgen intravenous pyelograpy
WHOQOL-BREF World Health Organization
Quality of Life-BREF
Questionnaire
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Introduction
Bladder cancer (BC) is the 7th most common cancer
worldwide. In the Netherlands, invasive BC was the 8th most
common cancer in 2008 [1]. Most patients are being diag-
nosed after presenting with gross or microscopic hematuria
[2, 3]. The golden standard for diagnosis of BC is a cystos-
copy of the bladder. When (muscle)-invasive bladder cancer
(MIBC) is found, the therapy of choice is the radical cys-
tectomy with bilateral pelvic lympadenectomy. Other cura-
tive treatment options are interstitial radiotherapy (IRT; e.g.,
brachytherapy for small solitary clinical stage II tumors) and
external beam radiotherapy (EBRT). When a patient is not
eligible for any of the above-mentioned therapies due to
comorbidity or preference, a non-curative option usually
follows: a transurethral resection of the bladder tumor
(TURBT) or palliative radiotherapy.
This complex operation is assumed to affect the
patient’s quality of life (QoL) and health status (HS), and
sexual functioning as it involves major surgery and having
an incontinent or continent urinary diversion. As a result,
HS and QoL, both patient reported outcomes, in patients
with MIBC undergoing cystectomy are a topic of much
interest in urologic oncology. A recent review of Somani
et al. [4] on QoL with urinary diversion stated that there is
an urgent need to establish the important determinants of
QoL of this patient group.
In the few existing prospective studies, baseline QoL is
assessed just prior to the cystectomy or shortly after sur-
gery. Psychological, HS, and, health-related QoL measures
return to or exceed baseline values [5–7]. In none of these
studies, the first measurement of QoL is done before
diagnosis of BC. However, being diagnosed with cancer
may already cause a changed perspective on QoL. A
baseline QoL measurement point before diagnosis can give
a more correct reflection of patients’ baseline QoL.
QoL is known to be influenced by health [8], culture [9],
social-economic status [10], and personality [11, 12].
Especially, the personality factor trait anxiety is associated
with QoL. Studies among breast cancer patients have
shown that an anxious personality will react differently to
having cancer and undergoing major surgery and will
experience a lower QoL compared with patients without
such a personality [13, 14].
As stated above, hematuria is the most common pre-
senting symptom of BC. The time before cystoscopy for
patients with primary hematuria can serve as a good
moment for a baseline measurement in QoL-studies on BC,
to use in comparison with postoperative measurements.
The aim of this multicenter study was to examine the
patient reported outcome measures QoL, HS, and sexual
function and dispositional anxiety in patients with BC
before diagnosis was known. The comparison group was
other patients with primary hematuria before cystoscopy




All consecutive patients presenting with primary hematuria
in one of six academic or large teaching departments of
urology (University Medical Centre Utrecht; St. Elisabeth
Hospital and Twee Steden Hospital, Tilburg; Onze Lieve
Vrouwe Gasthuis, Amsterdam; Jeroen Bosch Hospital, ‘s
Hertogenbosch; Catharina Hospital, Eindhoven) in the
Netherlands, between July 2007 and July 2010, were eli-
gible for this study. Exclusion criteria were age younger
than 18 years, a presumed life expectancy of less than
2 years, dementia, psychiatric disorders or insufficient
comprehension of the Dutch language.
Evaluation of the hematuria consisted of history and
examination, urinalysis, and cytology. In addition, most
patients underwent CT-IVP/urography or ultrasound and/or
X-IVP depending on the preference of the individual
urologist. Patients who underwent cystoscopy for evalua-
tion of gross or microscopic hematuria were included and
asked to complete a set of questionnaires on demographic
features, QoL, HS, sexual functioning, and trait anxiety.
Five hundred and ninety-eight patients (98.5 %) gave
informed consent and were asked to completed the ques-
tionnaires before undergoing a cystoscopy or radiological
diagnostics, that is, before the diagnosis was known
(Fig. 1). Reasons given for not participating or late
exclusion (after informed consent was given) were ‘ques-
tions too personal’, ‘not interested in participating after
reading the questionnaire’, questionnaire not completed
before diagnosis. The study was approved by the local
ethics committees. All patients provided written informed
consent.
Questionnaires
World Health Organization Quality of Life-BREF
Questionnaire (WHOQOL-BREF) [15, 16]
This questionnaire is the abbreviated version of the
WHOQOL-100 and consists of 26 items covering four
domains (Physical, Psychological, Social Relationships,
and Environment) and a global QoL and general health
facet. Patients also completed the three items from the facet
sexual activity from the WHOQOL-100 that are not part of
the WHOQOL-Bref. The reliability and validity are satis-
factory [17], and the sensitivity to change is good [18].
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RAND Medical Outcomes Study Short Form-12 (SF-12,
version 2) [19]
A 12-item adaptation of the RAND 36-Item Health Survey
(SF-36). The SF-12 quantifies health status into two com-
posite scores, the Physical Component Summary (PCS)
and Mental Component Summary (MCS) scales. In addi-
tion, the SF-12 quantifies health status into eight subscales,
including physical functioning, emotional well-being,
general health, pain, energy, social functioning, and role
limitations due to physical or emotional problems. The
summary scales are scored from 0 to 100 and converted to
a standardized scale with a population mean of 50 and a
standard deviation of 10. A higher score implies a better
health status. The reliability and validity are satisfactory
[19, 20].
State-Trait Anxiety Inventory-Trait scale short form (STAI-
10-item Trait) [21]
The STAI was originally developed to investigate anxiety
phenomena in ‘normal’ adults but has also proven useful in
medical and surgical patients. Trait anxiety concerns dif-
ferences in individuals in the disposition to respond to
stressful situations with varying amounts of stress. The
10-item trait scale (10 statements) asks people to describe
how they generally feel. A trait anxiety score of more than
21 was considered high. The psychometric characteristics
of this questionnaire are well established and considered
good [22].
International index of erectile function (IIEF) [23]
The IIEF is a validated, self-administered questionnaire
that assesses overall sexual function. It is divided into the 5
domains of erectile function, intercourse satisfaction,
orgasmic function, sexual desire, and overall satisfaction.
The IIEF demonstrates the sensitivity and specificity for
detecting treatment-related changes in patients with erectile
dysfunction [23]. After the first year of the study, it became
apparent that a significant part of the patients did not par-
ticipate in the study because of this questionnaire with its
sexually related questions. Therefore, from September
2009 onwards new patients did not receive the IIEF
questionnaire.
Demographic Questionnaire
Patients were asked to answer questions concerning age,
marital status, education, and work to evaluate social-
economic status.
Medical records
Data concerning medical diagnosis, tumor stage and grade
after pathological examination, and treatment were
obtained from the medical records of the patients with
informed consent.
Statistical procedure
Independent sample t tests and chi-square tests were used
to compare: (1) the participants and non-participants and
(2) to examine QoL and HS differences between the two
patient groups (bladder cancer vs. other causes of hema-
turia). Correction for covariates age and gender was done
with anova univariate analysis. Patients with other forms of
cancer were excluded from analyses. When comparing
muscle-invasive versus non-muscle-invasive bladder can-
cer (NMIBC) versus other causes of hematuria with regard
to trait anxiety, one way ANOVA was used. Analyzing
MIBC to NMIBC group on high anxiety scores, indepen-
dent sample t test was used. Analyses were performed with
the Statistical Package for Social Sciences (SPSS version
15.0).
Results
Four hundred and seventy-six patients (79.6 %) with
hematuria participated in this study and answered the
questionnaire (Fig. 1). Demographics and clinical features
of the participants and non-participants are shown in
Table 1. Participants and non-participants only differed
with regard to age, with participants being older. Diagnoses
of all patients (participants and non-participants) are shown
in Table 2. In 226 patients (37.8 %), no pathological
finding was detected. Cancer was diagnosed in 131 of the
Fig. 1 Flowchart study population
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598 patients (21.9 %), including 102 patients (17.1 %)
with BC. NMIBC was found in 71 patients (11.9 %) and
MIBC in 31 patients (5.2 %).
Of the participants, 110 patients had cancer (23.1 %)
and 87 patients had BC (18.3 %). Only one patient under
the age of 50 was diagnosed with BC. Most patients with
BC (69.6 %) were older than 60 years. Among the elderly
([75? years), 23.5 % had BC. Of the patients with BC,
78.4 % were men. Demographics and clinical features of
the patients with bladder cancer and with other causes are
shown in Table 3.
Patient reported outcomes
Patients’ scores on QoL, health status, sexual function, and
anxiety are shown in Table 4.
No significant differences were found for general QoL
and the four QoL domains. The SF-12 showed no differ-
ences on HS between patients with BC versus patients with
OC.
The IIEF showed a significant effect on erectile function
(p = 0.02) and orgasmic function (p = 0.05). OC patients
had better scores than BC. In line with this finding, erectile
dysfunction was highest among patients with BC (93 % vs.
OC 79 %).
The mean score of trait anxiety indicated normal anxiety
in both groups (BC and OC). Patients with MIBC had
significantly lower scores on trait anxiety compared with
the other BC patients (F = 4.94, p = 0.03), only 7 % of all
patients with MIBC had a high anxious personality in
comparison with 20 % in the NMIBC group and 25 % of
all patients (x2 = 1.18, p = 0.05).
Discussion
We examined the QoL, HS, sexual functioning, and dis-
positional anxiety in patients with BC before diagnosis was
known. The comparison group was other patients with
primary hematuria before cystoscopy had taken place.
Quality of life and health status
In the urologic oncology community, there is no stan-
dardized assessment protocol for QoL-studies, and a wide
variation exists in QoL-outcome studies [24]. A major
limitation is that the few prospective studies all report a
‘‘baseline’’ assessment of HS and/or QoL that is done, only
after MIBC is confirmed. However, the diagnosis cancer by
itself is an almost certain reason for a change in QoL. It
was our aim to assess QoL and HS before diagnosis in
order to get a good baseline assessment. Therefore, we
asked all patients with primary hematuria to complete
questionnaires on QoL, HS, sexual function, and level of
trait anxiety before a diagnosis was established. QoL-
studies for MIBC mostly involve only HS which is not
equivalent to QoL [7, 25]. HS indicates where there are
limitations in physical functioning as impact of the disease,
Table 1 Demographics and clinical features of the participants and non-participants
Participants (n = 476) Non-participants (n = 122) p value
Mean age (years ± SD) 62.5 (11.8) 59.5 (15) 0.05
Gender (male) 300 (63) 76 (62.3) 0.6
Diagnosis Benign/malignant 353 (74.2)/110 (23.1)/13 (2.7) 101 (82.8)/21 (17.2) 0.16
Diagnosis bladder cancer 87 (18.3) 15 (12.3) 0.12
NMIBCa 61 (70.1) 10 (66.7) 0.13
MIBCa 26 (29.9) 5 (41) 0.51
Cystectomy 18 (69.2) 3 (20) 0.44
EBRT 5 (19.2)
IRT(Brachytherapy) 3 (11.5)
Nationality (Dutch; missing) 450 (94.5)/10 (2.1)
Partner: yes/no/missing 378 (79.4)/77 (16.2)/21 (4.4)
Children: yes/no/missing 393 (82.6)/71 (14.9)/12 (2.5)
Education: low/high/missing 265 (55.7)/189 (39.7)/22 (4.6)
Paid work: yes/no/missing 176 (37)/265 (55.7)/35 (7.3)
Medication: yes/no/missing 345 (72.5)/118 (24.8)/13(2.7)
(N)MIBC (non-) muscle-invasive cancer, EBRT external beam radiotherapy, IRT interstitial radiotherapy
Besides for age, percentages are between brackets
a Percentages of bladder cancer patients
p values in bold are significant
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whereas QoL also reflects to what extent the patients are
bothered by these limitations in daily life [14, 26].
The current study shows that the patients with unknown
diagnosis of BC appeared to have the same baseline results
on QoL and HS in comparison with the patients with other
diagnosis. The BC patients perceived their sexual func-
tioning as lower, and they also had the lowest percentage of
anxious personalities.
Erectile dysfunction was highest (93.1 %) and orgasmic
function lowest among patients with BC compared with the
patients with other diagnoses. The underlying disease,
although not known by the patient, seems to have an
impact on his/her sexual life. Although it is known that
sexual function decreases after the cystectomy, the fact that
patients already have a decrease in function before diag-
nosis is new information [7, 27]. A history of smoking is a
known risk factor for BC, and the fact that smoking can
give rise to cardiovascular disease that is an important
cause of erectile dysfunction could be an explanation for
our finding.
Furthermore, patients with BC had the lowest percent-
age of anxious personalities (17 %), especially patients
with MIBC (7 %). This may be a reason for having a
higher-stage disease at presentation in the hospital as their
anxiety level prevents these patients from visiting their
doctor when symptoms first emerge. As this finding is
based on only 26 versus 61 patients with a significance of
p \ 0.03, further research with more power is needed for
confirmation.
Our study had strengths and limitations that merit
comment.
This prospective study is multicenter. To our knowl-
edge, this is the first study to investigate QoL in patients
with hematuria and to investigate pre-diagnosis QoL in
patients with bladder cancer. The best population to study
this research question would be the general population.
However, in the Netherlands in 2009, there were 5,100
cases of newly diagnosed bladder cancer, with a lifetime
cumulative risk of 2 % in a population of 16 million people
[1]. This low risk makes screening the general population
for the current research question unfeasible. As hematuria
is the key symptom of bladder cancer, the population
presenting with hematuria could be considered second best.
A limitation is the early withdrawal of the IIEF ques-
tionnaire. Particularly as the results of the patients who did
complete the IIEF showed a difference in sexual function.
Despite oral and written information about this question-
naire to patients when informing patients about the study,
the proportion of patients refusing participation due to the
IIEF made us decide to withdraw the list. Further limita-
tions are that no difference is made during the inclusion
between the two forms of hematuria, and the patients’
smoking history is unknown.
There are multiple studies on QoL after cystectomy [7,
25]. Most studies only use HRQoL questionnaires and do
not compare QoL and HS in the same study population. No
study has as yet addressed the issue of a baseline mea-
surement with an unknown diagnosis, as in our study. Our
study shows that pre-diagnosis QoL and HS do not differ
between patients with and without bladder cancer. A fol-
low-up study is initiated to evaluate QoL after cystectomy





Prostatic bleeding (BPH; chronic prostatitis) 67 11.2
Calculi (renal/ureteral) 32 5.3





Use of oral anticoagulation 8 1.3
Radiation cystitis 2 0.3
Renal cyst with bleeding 3 0.5
Urethral or meatal pathology 10 1.7
Crohn’s disease 1 0.2
Bladder wall-necrosis 1 0.2
Nephrogenic cause 7 1.2
Lost to follow-up 13 2.2
Renal cancer 12 2.0
Ureteral malignancy 5 0.8
Colon cancer 3 0.5
Ovarium cancer 1 0.2
Endometrium cancer 2 0.3
Prostate cancer 6 1.0
Bladder cancer 102 17.1
Total 598 100
Table 3 Demographics and clinical features of the patients with
bladder cancer and other causes
Bladder cancer Other causes p value
Mean age (years ± SD) 66.3 (9.5) 61.3 (12.3) 0.00
Gender (male) 68 (77.9) 220 (62.9) 0.01
Nationality (Dutch) 83 (95.4) 335 (94.9) 0.62
Partner 70 (80) 284 (81) 0.33
Children 69 (79.3) 294 (83.5) 0.12
Education 27 (31) 148 (42) 0.17
Paid work 28 (31) 138 (39.2) 0.46
Medication 59 (67.8) 264 (74.8) 0.37
Besides for age, percentages are between brackets
p values in bold are significant
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for BC using this baseline measurement with an unknown
diagnosis and to see how QoL is affected by the surgery.
In conclusion, cancer was found in 21.9 % of the
patients with hematuria.
Pre-diagnosis patients with BC have comparable QoL
and HS to patients with OC. Erectile dysfunction was
highest in patients with BC. Patients with MIBC had the
lowest percentage of anxious personalities.
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Table 4 Scores for quality of life, health status, sexual function, and anxiety separately for patients with bladder cancer versus patients with





p value with co-variate
model age and gender
WHOQOL-BREF
Overall QoL and general health 3.8 (0.8) [87] 3.7 (0.8) [353] 0.31
Physical health (domain 1) 14.8 (2.8) [87] 14.5 (3.0) [350] 0.56
Psychological health (domain 2) 14.9 (2.1) [87] 14.8 (2.3) [352] 0.73
Social relationships (domain 3) 14.0 (3.4) [87] 14.4 (3.2) [351] 0.77
Environment (domain 4) 15.7 (2.2) [87] 15.8 (2.4) [351] 0.76
Sexual satisfaction 11.1 (4.4) [87] 12.1 (4.7) [351] 0.34
SF-12
General health perceptions 46.6 (19.9) [87] 45.7 (20.3) [352] 0.70
Physical functioning 73 (30) [87] 74.4 (31) [351] 0.96
Social functioning 19.1 (18.3) [87] 19.8 (19.4) [346] 0.90
Role limitations physical 66.7 (46.2) [87] 60.5 (46.2) [351] 0.44
Role limitations emotional 90.3 (38.8) [87] 81.7 (35.2) [346] 0.10
General mental health 72.9 (16.8) [87] 70.5 (18.6) [347] 0.53
Energy/fatigue 60.7 (25.2) [87] 56.4 (25.3) [347] 0.39
Bodily pain 76.2 (22.9) [87] 75.5 (23.6) [345] 0.93
Physical component scale 65.6 (22.7) [87] 64.5 (24.9) [343] 0.80
Mental component scale 60.7 (14.9) [87] 57.2 (14.5) [342] 0.15
IIEF
Erectile function 9.3 (8.1) [29] 14.6 (9.2) [80] 0.02
Patients with ED (cutoff 25 points)* 93.1 % 78.8 %
Intercourse satisfaction 4.1 (5.1) [32] 6.8 (5.9) [87] 0.07
Orgasmic function 3.4 (3.9) [31] 5.3 (4.2) [89] 0.05
Sexual desire 4.5 (2.0) [29] 5.1 (2.1) [89] 0.26
Overall satisfaction 5.1 (2.5) [25] 6.2 (2.5) [81] 0.17
Trait anxiety 16.9 (4.9) [85] 17.6 [340] 0.29
High score on anxiety (score C22) 16.5 % 24.7 % 0.15
ED erectile dysfunction
Patients with other forms of cancer were excluded from analyses
Scores are represented in means. SD are between brackets
Number of questionnaires with the item completed between square brackets
p values in bold are significant
* Erectile dysfunction with cut-off point at 25 points
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